Jubilant Pharmova receives ANDA approval for Doxepin Hydrochloride Capsules

22 Mar 2022 , 04:47 PM

Jubilant Pharmova Limited, an integrated global Pharmaceuticals Company, has announced that Jubilant Pharma Limited, a material wholly-owned subsidiary of the Company, through one of its subsidiaries, Jubilant Cadista Pharmaceuticals Inc. has received Abbreviated New Drug Application (ANDA) final approval for Doxepin Hydrochloride Capsules, 10 mg, 25mg, 50mg, 75mg, and 100mg, the generic version of Sinequan®.

It is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis, the company said.

As on December 31, 2021, Jubilant’s Pharmaceuticals business had a total of 98 ANDAs for Oral Solids filed in the US, of which 61 have been approved and 4 Injectable/Opthalmic filings, of which 2 have been approved.